{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:34:49Z","timestamp":1790778889544,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1986,1,1]],"date-time":"1986-01-01T00:00:00Z","timestamp":504921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1986]]},"DOI":"10.1007\/bf00613515","type":"journal-article","created":{"date-parts":[[2004,11,25]],"date-time":"2004-11-25T04:23:31Z","timestamp":1101356611000},"page":"411-414","source":"Crossref","is-referenced-by-count":7,"title":["Inhibition of thrombocyte aggregation by oral motapizone and other drugs"],"prefix":"10.1007","volume":"31","author":[{"given":"V.","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Hanselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Huhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Zietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","unstructured":"Prop G, Doppelfeld IS (1985) Motapizone ? Cardiovascular and antithrombotic activity. Naunyn-Schmiedebergs Arch Pharmacol 329: R 61"},{"key":"CR2","unstructured":"Doppelfeld IS, Hilboll G, Prop G (1985) Motapizone, its cardiotonic properties. Naunyn-Schmiedebergs Arch Pharmacol 330: R 42"},{"key":"CR3","unstructured":"Borbe HO, Hilboll G, Kuhl P (1985) Motapizone, a new pyridazinone derivative with potent antiaggregatory properties. Naunyn-Schmiedebergs Arch Pharmacol 329: R 61"},{"key":"CR4","unstructured":"Borbe HO, Hilboll G (1985) Effects of motapizone on the cAMP-levels of human platelets. Naunyn-Schmiedebergs Arch Pharmacol 330: R 23"},{"key":"CR5","first-page":"210","volume":"54","author":"AK Sim","year":"1985","unstructured":"Sim AK, McCraw AP, Borbe HO, Wetzig H (1985) Motapizone, a novel antihypertensive drug with potent antithrombotic activity. Thromb Haemostas 54: 210","journal-title":"Thromb Haemostas"},{"key":"CR6","unstructured":"Schulz V, Esser U, Fischer W (1986) The inhibition of thrombocyte aggregation through motapizone: comparison ?in vitro? with 19 commercial preparations. Naunyn-Schmiedebergs Arch Pharmacol (in press)"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00613514","volume":"31","author":"V Schulz","year":"1986","unstructured":"Schulz V, Fischer W, Hanselle U, Huhmann W, Zietsch V (1986) The hypotensive and antiplatelet actions of motapizone in dependence on the dose and the time after oral ingestion. Eur J Clin Pharmacol 31: 405?410","journal-title":"Eur J Clin Pharmacol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/clpt.1983.47","volume":"33","author":"DJ Siebert","year":"1983","unstructured":"Siebert DJ, Bochner F, Imhoff DM, Watts S, LLoyd JV, Field J, Gabb BW (1983) Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther 33: 367?374","journal-title":"Clin Pharmacol Ther"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.V61.6.1081.1081","volume":"61","author":"G Minno Di","year":"1983","unstructured":"Di Minno G, Silver MJ, Murphy S (1983) Monitoring the entry of new platelets into the circulation after ingestion of aspirin. Blood 61: 1081?1085","journal-title":"Blood"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1055\/s-0038-1661214","volume":"52","author":"MA Packham","year":"1984","unstructured":"Packham MA (1984) Standardisation of collagen: Consideration of current practices in testing collagen-induced aggregation. Thromb Haemostas 52: 358?361","journal-title":"Thromb Haemostas"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0038-1661277","volume":"53","author":"SG Thompson","year":"1985","unstructured":"Thompson SG, Vickers MV (1985) Methods in dose response platelet aggregometry. Thromb Haemostas 53: 216?218","journal-title":"Thromb Haemostas"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-0038-1661278","volume":"53","author":"MV Vickers","year":"1985","unstructured":"Vickers MV, Thompson SG (1985) Sources of variability in dose response platelet aggregometry. Thromb Haemostas 53: 219?220","journal-title":"Thromb Haemostas"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0049-3848(80)90034-1","volume":"19","author":"K Breddin","year":"1980","unstructured":"Breddin K, Ziemen M, Bauer O, Herrmann W, Schaudinn L, Schlosser U, Winterhagen A, Krzywanek HJ (1980) Time and temperature changes of ADP- and collagen-induced and ?spontaneous? aggregation. Thromb Res 19: 621?638","journal-title":"Thromb Res"},{"key":"CR14","first-page":"164","volume-title":"Advances in ?-blocker therapy","author":"WH Frishman","year":"1980","unstructured":"Frishman WH, Weksler BB (1980) Effects of ?-adrenoceptor blocking agents on platelet function in normal subjects and patients with angina pectoris. In: Roskamm H, Graefe KH (eds) Advances in ?-blocker therapy. Excerpta Medica, Amsterdam Oxford Princeton, pp 164?188"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1016346913143","volume":"1985","author":"PH Rolland","year":"1985","unstructured":"Rolland PH, Sampol J, Lacarelle B, Arnoux D, Leca F, Gueydon E, Cano JP (1985) Differential inhibitory effects of isosorbide dinitrate and its mononitrate metabolites on platelet aggregation and thromboxane formation. Pharm Res 1985: 87?90","journal-title":"Pharm Res"},{"key":"CR16","first-page":"1401","volume":"33","author":"CA Bouvier","year":"1983","unstructured":"Bouvier CA (1983) Calcium antagonists and platelet function. Arzneimittelforsch 33: 1401?1405","journal-title":"Arzneimittelforsch"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/0002-8703(85)90408-9","volume":"109","author":"K Takahara","year":"1985","unstructured":"Takahara K, Kuroiwa A, Matsushima T, Nakashima Y, Takasugi M (1985) Effects of nifedipine on platelet function. Am Heart J 109: 4?8","journal-title":"Am Heart J"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF01537481","volume":"63","author":"K Schroer","year":"1985","unstructured":"Schroer K, Latia G, Darius H, Klaus W, Ziegler R (1985) Hemmung der Pl\u00e4ttchenaggregation and thromboxanbildung durch den Calcium-Antagonisten Nisoldipin nach einer oralen Einmaldosis von 10 mg. Klin Wochenschr 63: 16?19","journal-title":"Klin Wochenschr"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0049-3848(83)90035-X","volume":"32","author":"J Ambler","year":"1983","unstructured":"Ambler J, Sarwar M, Smith JR, Wallis RB (1983) The platelet inhibitory effect of hydralazine: Comparison with hypotensive effects in the rat. Thromb Res 32: 239?243","journal-title":"Thromb Res"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/00005344-198409000-00016","volume":"6","author":"N Someya","year":"1984","unstructured":"Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K (1984) Supressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol 6: 840?843","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.CIR.62.3.449","volume":"62","author":"Persantine-Aspirin Reinfarction Study Group","year":"1980","unstructured":"Persantine-Aspirin Reinfarction Study Group (1980) Persantine and aspirin in coronary heart disease. Circulation 62: 449?461","journal-title":"Circulation"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","volume":"309","author":"Veterans Administration Cooperative Study Group","year":"1983","unstructured":"Veterans Administration Cooperative Study Group (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 309: 396?403","journal-title":"N Engl J Med"},{"key":"CR23","first-page":"253","volume":"3","author":"CN Chesterman","year":"1982","unstructured":"Chesterman CN, Gallus AS, Penington DG (1982) Platelets, the vessel wall and antiplatelet drugs. Recent Adv Haematol 3: 253?283","journal-title":"Recent Adv Haematol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1097\/00005344-198111000-00026","volume":"3","author":"F Clerck De","year":"1981","unstructured":"De Clerck F, David JL (1981) Pharmacological control of platelet and red blood cell function in the microcirculation. J Cardiovasc Pharmacol 3: 1388?1412","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/clpt.1985.8","volume":"37","author":"AK Pedersen","year":"1985","unstructured":"Pedersen AK, FitzGerald GA (1985) Cyclooxigenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther 37: 36?42","journal-title":"Clin Pharmacol Ther"},{"key":"CR26","unstructured":"Gordon JL (1984) Ticlopidine: Quo vadis? Agents and actions. Supplement 15"},{"key":"CR27","first-page":"317","volume":"12","author":"M Verstraete","year":"1982","unstructured":"Verstraete M (1982) A pharmacological approach to the inhibition of platelet adhesion and platelet aggregation. Haemostasis 12: 317?336","journal-title":"Haemostasis"},{"key":"CR28","volume-title":"Platelets ? Pathophysiology and antiplatelet drug therapy","author":"HJ Weiss","year":"1983","unstructured":"Weiss HJ (1983) Platelets ? Pathophysiology and antiplatelet drug therapy. A. R. Liss, New York"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00613515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00613515\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00613515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T08:36:34Z","timestamp":1585989394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00613515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1986]]}},"alternative-id":["BF00613515"],"URL":"https:\/\/doi.org\/10.1007\/bf00613515","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986]]}}}